Form 4: NEOGENOMICS Director Alison Hannah Reports Significant Equity Holdings and Recent Grants

NEOGENOMICS Director Alison L. Hannah has filed a Form 4, disclosing the vesting of 12,254 restricted stock units and the grant of new equity awards, including 16,107 stock options and 23,077 restricted stock units, effective June 1, 2025.

Summary

• Alison L. Hannah, a Director of NEOGENOMICS INC (NEO), filed a Form 4 on June 3, 2025, detailing changes in her beneficial ownership.
• Effective June 1, 2025, Ms. Hannah acquired 12,254 shares of common stock at a price of $0, resulting from the vesting and release of previously reported restricted stock units.
• Following this transaction, Ms. Hannah's direct beneficial ownership of NEOGENOMICS common stock increased to 131,023 shares.
• The filing also reports the grant of new derivative securities, including 16,107 stock options with an exercise price of $7.28, which become exercisable on June 1, 2026, and expire on June 1, 2035.
• Additionally, 23,077 new restricted stock units were granted, also effective June 1, 2025, which will become exercisable on June 1, 2026, and convert to common stock upon vesting without an expiration date.
• The document lists several other existing stock options held by Ms. Hannah with various exercise prices ranging from $8.10 to $40.90 and expiration dates extending through 2034.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased beneficial ownership and continued receipt of equity incentives, which is generally a positive sign of alignment between management and shareholder interests. It's a routine filing, so the sentiment is neutral to slightly positive, reflecting normal business operations and compensation.

Positives

• Director Alison L. Hannah's beneficial ownership of common stock increased to 131,023 shares, indicating continued alignment with shareholder interests.
• The vesting of 12,254 restricted stock units at a $0 price represents a direct equity gain for the director, reflecting past performance incentives.
• The grant of new stock options (16,107 units) and restricted stock units (23,077 units) signifies ongoing compensation and incentives for the director, aligning her long-term interests with the company's future performance.

Future Outlook

The document indicates future vesting dates for newly granted restricted stock units and exercisable dates for new stock options, extending into 2026 and beyond, with expiration dates for options as far out as 2035. This reflects the long-term incentive structure for the director.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions. It reflects standard corporate governance practices where directors receive equity-based compensation, aligning their interests with long-term shareholder value. Such filings are common across all industries for publicly traded companies.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership and ongoing equity incentives align the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Future vesting of 23,077 restricted stock units on or after June 1, 2026.
• Future exercisability of 16,107 stock options on or after June 1, 2026.

Key Dates

Recommendation

Keywords

NEOGENOMICS INC, NEO, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Awards